Clinical Trials Browser

Neuroendocrine Tumors

Thyroid Neoplasms

Uterine Cervical Neoplasms

Endometrial Neoplasms

Carcinoma, Renal Cell

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Carcinoma, Renal Cell

Differentiated Thyroid Cancer

Cholangiocarcinoma

Endometrial Neoplasms

Solid Tumors

Carcinoma, Hepatocellular

Carcinoma, Squamous Cell

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Carcinoma, Renal Cell

Adenocarcinoma, Uterine Cervical Neoplasms

Sarcoma, Kaposi

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Renal Cell

Advanced Gastric Adenocarcinoma

Adenocarcinoma, Neoplasms

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Carcinoma, Renal Cell

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Carcinoma, Hepatocellular, Liver Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Hepatocellular

Vulvar Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Carcinoma, Renal Cell

Biliary Tract Neoplasms Immunotherapy

Leiomyosarcoma, Liposarcoma, Sarcoma

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Hepatocellular

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Stomach Neoplasms

Pancreatic Neoplasms

Skin Neoplasms, Carcinoma, Merkel Cell

Brain Neoplasms, Neoplasms

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Recurrence, Endometrial Neoplasms

Breast Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

PRELUDE

HAIC-quad

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

PLUTO

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

PULSAR

MAGNATE-S

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

SAMURAI

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

LaPemERLA

FRONT-1

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

MITO VULVA-01

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Neo PeLe

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

LEADER

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

PLUME

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer